16 September 2021 
EMA/CHMP/526207/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Segluromet 
ertugliflozin / metformin hydrochloride 
On 16 September 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Segluromet. The marketing authorisation holder for this medicinal product is Merck Sharp & Dohme B.V. 
The CHMP adopted an extension to the existing indication as follows:2  
Segluromet is indicated in adults for the treatment of aged 18 years and older with type 2 diabetes 
mellitus as an adjunct to diet and exercise to improve glycaemic control: 
• 
• 
• 
in patients not adequately insufficiently controlled on their maximally tolerated dose of 
metformin alone 
in combination with in patients on their maximally tolerated doses of metformin in addition 
to other medicinal products for the treatment of diabetes in patients insufficiently 
controlled with metformin and these products 
in patients already being treated with the combination of ertugliflozin and metformin as 
separate tablets.  
(For study results with respect to combinations of therapies, and effects on glycaemic control, 
cardiovascular events and the population studied, see sections 4.4, 4.5 and 5.1.) 
For information, the full indication is as follows: 
Segluromet is indicated in adults for the treatment of type 2 diabetes mellitus as an adjunct to diet 
and exercise: 
• 
• 
in patients insufficiently controlled on their maximally tolerated dose of metformin alone 
in combination with other medicinal products for the treatment of diabetes in patients 
insufficiently controlled with metformin and these products  
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
in patients already being treated with the combination of ertugliflozin and metformin as 
separate tablets.  
For study results with respect to combinations of therapies, effects on glycaemic control, 
cardiovascular events and the population studied, see sections 4.4, 4.5 and 5.1. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
Segluromet  
EMA/CHMP/526207/2021 
Page 2/2 
 
 
 
 
 
 
 
 
